阿尔茨海默病早期诊疗迈入“精准医学”新时代

Advancing into a new era of precision medicine in early diagnosis and treatment of Alzheimer′s disease

近年来,阿尔茨海默病(AD)的早期精准诊断与治疗领域取得了显著进展,给传统模式带来了革命性的变革。针对这些创新发展,中华医学会神经病学分会痴呆与认知障碍学组从我国医疗体系与患者需求出发,制订并发布了《阿尔茨海默病源性轻度认知障碍诊疗中国专家共识2024》。该共识搭建了一个系统、综合的诊疗框架,不仅为实际临床诊疗提供了切实可行的指导方案,也为AD精准防治的新阶段奠定基础。基于此,我们就AD早期诊疗的生物标志物、临床诊断标准、疾病分期以及早期干预策略发展做了深入评论,旨在帮助临床及科研工作者构建一个全面的AD早期精准诊疗体系,并强调在AD早期精准识别和管理的重要性,推动AD早期诊疗工作进入“精准医学”的新时代。

In recent years,precision medicine has made significant progress in the early diagnosis and treatment of Alzheimer′s disease(AD),bringing revolutionary changes to traditional models.In response to these innovative developments,the Chinese Society of Dementia and Cognitive Impairment,starting from the needs of China′s healthcare system and patients,has formulated and released the"Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to Alzheimer′s disease 2024".This consensus establishes a systematic and comprehensive diagnostic and therapeutic framework,which not only provides practical guidelines for implementation but also lays a solid foundation for the new stage of precise prevention and treatment of AD.Based on this,in-depth discussions and comments were conducted on AD′s biomarkers,clinical diagnostic criteria,disease staging,and early intervention strategies,aiming to assist clinical and research professionals in constructing a comprehensive AD precision medicine system and to emphasize the importance of early precision recognition and management of the disease,thus advancing early diagnostic and therapeutic efforts for AD into a new era of precision medicine.